MGI, a company engaged in the development of innovative tools and technologies in the life sciences, announced its collaboration with SeqOne, a start-up specializing in the development of decision support tools driven by AI, in order to develop and validate end-to-end genomic analysis solutions, from sample to report, tailored to the needs of human genetics and pathology laboratories around the world.
This collaboration between MGI and SeqOne encompasses three distinct initiatives:
Validation of an end-to-end, automated and cost-effective solution for HR signature with MGI’s DNBSEQ-G99
Collaboration between a pathology reference laboratory in Spain, Agilent Technologies, MGI and SeqOne aims to technically validate a routine workflow using Agilent panels, Magnis library preparation automation, MGI’s DNBSEQ-G99 and SeqOne somaHRD, a clinically validated HRD signature solution on 96 samples.
This end-to-end solution designed for molecular pathology laboratories will enable high-quality, efficient and flexible HRD analyzes worldwide, including genomic instability scoring and BRCA testing.
Also Read: Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
Implementation and validation of compatibility of SeqOne’s tertiary analysis solution with MGI Megabolt for germline panels, whole exome and whole genome
The MegaBOLT Bioinformatics Analysis Accelerator, a dedicated sequencing data analysis system, developed by MGI, is designed to provide seamless integration and compatibility with SeqOne’s variant identification and analysis solution, powered by AI.
This collaboration aims to combine MegaBOLT and the SeqOne platform to offer a versatile, accessible, intuitive and rapid solution, from sample to report, of particular interest for high-throughput human genetics laboratories.
Validation of the SeqOne CE-IVD platform for germline and somatic analysis for use with MGI sequencers in routine diagnostics
This technical validation project aims to evaluate the compatibility of the SeqOne platform with MGI sequencing data. It will validate the performance of variant calling on a set of reference control samples in terms of quality control, sensitivity and precision.
We are delighted to announce our collaboration with SeqOne. By combining MGI’s cutting-edge sequencing technology with SeqOne’s innovative genomic analysis platform, we are ready to provide real-world insights and solutions for personalized healthcare,” said Dr. Yong Hou , Managing Director of MGI Europe and Africa. “This collaboration underscores our commitment to advancing genomics research and providing clinicians with the tools they need to deliver tailored treatments to their patients. »
“This partnership with MGI strongly supports SeqOne’s mission to expand access to genomic analysis, with the goal of improving patient care,” said Martin Dubuc , CEO of SeqOne. “Molecular biology laboratories around the world are exploring how MGI’s sequencing and bioinformatics technologies can advance next-generation sequencing (NGS) research and diagnostics. We look forward to integrating SeqOne’s CE-IVD platform with MGI’s offerings to improve the quality, sensitivity and accuracy of bioinformatics analyses.
SOURCE: PRNewswire